We are live on ! Find out more
CTNM

Contineum Therapeutics

62 hedge funds and large institutions have $206M invested in Contineum Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,500% more call options, than puts

Call options by funds: $232K | Put options by funds: $2K

271% more capital invested

Capital invested by funds: $55.4M → $206M (+$150M)

8.42% more ownership

Funds ownership: 72.53%80.95% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

11% less funds holding

Funds holding: 7062 (-8)

36% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 22

Holders
62
Holders Change
-8
Holders Change %
-11.43%
% of All Funds
0.81%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
18
Reduced
18
Closed
22
Calls
$232K
Puts
$2K
Net Calls
+$230K
Net Calls Change
+$230K
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
76
Citigroup
New York
-$7.04K -1,774 Closed
JP Morgan Chase
77
JP Morgan Chase
New York
-$4.4K -1,108 Closed
HCA
78
Harbor Capital Advisors
Illinois
-$1K -145 Closed
PD
79
Point72 (DIFC)
United Arab Emirates
-$258 -65 Closed
GI
80
GAMMA Investing
California
-$238 -60 Closed
Nisa Investment Advisors
81
Nisa Investment Advisors
Missouri
-$183 -46 Closed
CA
82
Clearstead Advisors
Ohio
-$132 -33 Closed
CSS
83
Cubist Systematic Strategies
Connecticut
-$95 -24 Closed
Osaic Holdings
84
Osaic Holdings
Arizona
-$70 -10 Closed

CTNM Hedge Fund Activity: Q3 2025 in Review

62 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q3 2025, worth a combined $206M — up 271% from $55.4M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of CTNM and 14 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 18 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $17.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $1.89M.

  • 62 institutional investors held Contineum Therapeutics (CTNM) as of Q3 2025, down from 70 in Q2 2025.
  • Funds reported $206M of Contineum Therapeutics stock for Q3 2025, up 271% quarter-over-quarter.
  • 14 funds opened new Contineum Therapeutics positions in Q3 2025 and 22 closed out, a net change of -8 holders.
  • The largest Contineum Therapeutics buyer in Q3 2025 was RA Capital Management, an estimated $17.1M added.
  • The largest Contineum Therapeutics seller in Q3 2025 was Baker Bros. Advisors, an estimated $1.89M sold.

Based on aggregated 13F filings for Q3 2025.